Pharmacogenetics and ethnically targeted therapies

doi:10.1136/bmj.330.7506.1508-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Racial drugs need to be put in context

Jonathan D Kahn, assistant professor of law (jkahn01@hamline.edu)

Hamline University School of Law, 1526 Hewitt Avenue, St Paul, MN 55104, USA

EDITOR—Rahemtulla and Bhopal focus on the heart failure drug BiDil to explore the “resurgence of the role of biology in concepts of race and ethnicity.”1 BiDil, a combination of two generic drugs (hydralazine and isosorbide dinitrate) that have been used for years to treat heart failure, is currently undergoing review by the US Food and Drug Administration …